JAGSNPHARMNSEJagsonpal Pharmaceuticals Limited· PharmaceuticalsMediumNeutral
Announced Wed, 24 Sept · 18:02 IST

Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2025

Board & Shareholder Meetings View source PDF

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Jagsonpal Pharmaceuticals held its 46th Annual General Meeting on September 24, 2025, via Video Conferencing, from 3:30 PM to 4:23 PM, chaired by Non-Executive Chairman Mr. Harsha Raghavan. The meeting covered adoption of audited financial statements for FY ending March 31, 2025, declaration of dividend for FY25, and reappointment of Managing Director Mr. Manish Gupta (who retires by rotation). Members also approved ratification of remuneration for Cost Auditors Kirit Mehta & Co. for FY26, and a special resolution on revising the Managing Director's remuneration. Additionally, an appointment of a Secretarial Auditor was tabled. The Chairman and MD briefed members on company operations, achievements, and future outlook, and responded to shareholder queries. E-voting results will be announced within 2 working days by the scrutinizer Mr. Ayush Khandelwal.

Likely market impact

Routine AGM proceedings with a key highlight being the proposed revision in Managing Director's remuneration (passed as a special resolution) and FY25 dividend declaration. Voting results, expected within 2 working days, will confirm shareholder approval and could influence sentiment around the stock.